Assessing the tumor microenvironment has proved to be immensely informative in the context of clinical trials. Multiplex immunohistochemistry is the best suitable technology, allowing spatial detection and quantification of complex immune cell phenotypes.
Thanks to the unique HalioDx’ Brightplex® technology, pharma companies can access customized panels, providing valuable data and insights to further understand the mechanism of action of their drugs.
MTL-CEBPA is a small activating RNA therapeutic (saRNA) which, when combined with sorafenib, induces a novel myeloid differentiation in patients with advanced hepatocellular carcinoma (HCC).
HalioDx has specifically developed 3 Brightplex® panels, containing up to seven biomarkers each, for the identification and the quantification of different myeloid cells such as myeloid derived suppressor cells (MDSCs), neutrophils (N1/N2) and M1 and M2 macrophages on treated patient samples.
This technology, which uses one FFPE slide per panel, was rolled out to explore these changes by comparing pre- and post-treated samples from patients who have received MTL-CEBPA in combination with sorafenib during a Phase I a/b of a clinical trial study.
Nagy Habib, Professor of Surgery, Imperial College London; Co-Founder, MiNA Therapeutics
Professor Nagy Habib is Head of HPB Surgery at the Hammersmith Campus of Imperial College London and Co-Founder, MiNA Therapeutics. He is also a serial founder and entrepreneur of life sciences ventures. He is the co-founder of several biotech companies: EMcision Ltd, OmniCyte Ltd, Apterna Ltd, Medeva Plc and Bioenvision Ltd. Previously, he was Pro-Rector for Commercial Affairs at Imperial College London.
He is a translational researcher who pioneered the first clinical trial on the use of plasmid and adenovirus for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He was the Principal Investigator of the world’s first clinical trials published on the use of adult bone marrow-derived stem cells for the treatment of patients with liver insufficiency and CD34+ cells for patients with stroke. He was the inventor and co-author on the first publication to describe the use of radio frequency energy in devices for liver surgery (Habib 4X), and interventional endoscopy (Habib™ EndoHPB and Habib™ EUS-RFA).
Jacques Fieschi, PhD, VP of R&D, HalioDx
Jacques Fieschi is in charge of the Research & Development Department of HalioDx that develops tests and methods to grow the pipeline of the Diagnostic and Pharma Business Units of the Company. Previously, he has occupied different positions within the Immunodiagnostic branch of Beckman-Coulter, leading the development of several immunoassays, then joined QIAGEN Marseille as Head of Program Management. Dr. Fieschi received his PhD degree in immunology from Aix-Marseille University.
Who Should Attend?
This webinar will appeal to individuals with the following or related job titles:
- Translational Research / Cancer Research Scientists
- Directors of Immuno-Oncology Programs / Biomarker sciences / Companion Diagnostics / Profiling
- Clinical Trial Managers / Directors / VP
Working in the following research areas:
- Biomarker discovery
- Clinical Trial
What You Will Learn
- How the TME with multiplex immunohistochemistry is crucial for deciphering drug mechanisms of action on immune cells
- What type of meaningful data is obtained on pre- and post-treated patient samples
HalioDx is an immuno-oncology diagnostic company providing oncologists and Biopharma with first-in-class immune-based diagnostic products and services to guide cancer care and contribute to precision medicine in the era of immunotherapy and combination therapies.
Thanks to the pioneering work of Dr Jérôme Galon, HalioDx provides a unique range of immune scoring solutions – notably with the flagship Immunoscore® assay – allowing the assessment of the immune contexture of tumor, a key determinant of patient outcomes and response to cancer treatments (from preclinical stage to approved therapies).
To address the needs of Biopharmas, HalioDx has developed innovative technologies such as Multiplex Spatial Tissue Analysis (Brightplex®), molecular testing (NGS, Immunosign® Gene Expression Signatures) and customizable solutions such as TMExplore TM to capture the complexity of the Tumor Micro-Environment and Immunogram, a platform integrating Immunoscore® assays.
HalioDx has an experienced team of more than 170 employees, CLIA-certified laboratories and compliant facilities in Europe and in the US to develop, manufacture, register and market in vitro diagnostic (IVD) products. The company co-founded the European immunology cluster Marseille Immunopôle (MI).